Boston Scientific Corp. (NYSE: BSX) reported Q2 EPS of $0.18, $0.01 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.87 billion.

For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.